Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2007

Millenia Hope and Suninvest Sign Deal to Establish Antimalaria Drug Production Plant

  • Millenia Hope signed a memorandum of understanding with Suninvest of Angola, Africa, to establish a production facility in Angola for an antimalaria drug. This plant will supply an envisioned 500,000-treatment Malarex/MMH 18 order from the Angolan government once it has been homologated. The agreement extends the supply to the rest of the African region as well.

    “We are very pleased to have concluded this crucial MOU with Suninvest,” says Leonard Stella, chairman, and CEO of Millenia Hope. “Once the infrastructure is in place, we will have a true African presence in our ongoing battle against the devastation of malaria in the African continent.”

    Millenia Hope, a Montreal-based U.S. Biopharma, states that it has dedicated its resources for the past nine years to developing its antimalarial drug, Malarex/MMH 18.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »